Print this page    •   Back to Web version of article

Medical News
Lofty Hopes Confront Gilead's Four-Drug HIV Pill

September 12, 2011

Results are expected this month in the second pivotal clinical trial of Gilead Sciences Inc.'s four-in-one HIV treatment. Known as "Quad," the pill combines the experimental integrase inhibitor elvitegravir and the boosting agent cobicistat with Truvada, which contains Gilead's older HIV drugs Emtriva and Viread. If approved, Quad would be the first single-tablet HIV regimen to include an integrase inhibitor, which seeks to block HIV's ability to replicate. Currently, the only integrase inhibitor to gain approval is Merck & Co. Inc.'s Isentress (raltegravir), which must be taken twice daily. Gilead said in August that its first pivotal trial of Quad met the goal of showing it worked as well as Atripla, Gilead's three-drug HIV pill; analysts, however, say it may need to show superiority to convince investors of its potential. A lower-cost generic version of Atripla could be on the market in 2018. Full safety data from the first trial will be presented at a medical conference in March; Gilead plans to submit Quad for U.S. regulatory approval in the first quarter of 2012.

Back to other news for September 2011

Excerpted from:
Reuters
09.09.2011; Deena Beasley




This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. You can find this article online by typing this address into your Web browser:
http://www.thebody.com/content/63898/lofty-hopes-confront-gileads-four-drug-hiv-pill.html

General Disclaimer: TheBody.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBody.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.